AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03230539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate IUS delivering Cu and 5μg
Description: This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
Study NCT03230539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate IUS delivering Cu and 20μg
Description: This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
Study NCT00523081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Teens in the active control arm will keep seeing their doctor as usual. Teens and a parent are interviewed briefly over the phone to see if they are appropriate for the study. If they qualify for the study, there is an hour-long interview with teen over the telephone and a 30 minute interview with the parent. They will be interviewed six more times in the next two years.
Study NCT02085109 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fat milkshake
Study NCT03230539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal Acetate IUS delivering Cu and 40μg
Description: This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
Study NCT02735382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco quitline EHR referral
Description: Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.
Study NCT02735382 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco quitline Fax referral
Description: Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.
Study NCT02369874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 Monotherapy
Study NCT02369874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736 + Tremelimumab
Description: MEDI4736 + Tremelimumab combination therapy
Study NCT02369874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care
Study NCT00758628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromefenac
Description: Bromfenac BID 3 months
Study NCT00758628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Blink
Description: Blink BID for 3 months
Study NCT01503866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bardoxolone methyl
Description: oral, single dose
Study NCT04081727 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zip-stitch(TM)
Description: The assigned intervention is used to close the cuff following colpotomy.
Study NCT04081727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zip-stitch(TM)
Description: The assigned intervention is used to close the cuff following colpotomy.
Study NCT02085109 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fat milkshake
Study NCT01347138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: case management
Description: confirmation of hospital visit date, checking the adverse effect and treatment compliance
Study NCT02085109 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Theobromine
Study NCT01802125 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03303833 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational study.
Study NCT03288922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited BF OL-HDF with SHF
Description: The new modality Limited BF OL-HDF with SHF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 300 ml/min and the total dialysis fluid flow rate was 800 ml/min which included pre-filter substitution rate of 150 ml/min. The super high-flux dialyzer was PES-17Dα from Nipro Corporation, Japan which contains 1.7 m2 hollow fiber polyethersulfone membrane (ultrafiltration coefficient 80 ml/h/mmHg; urea clearance 267 ml/min, Qb 300 ml/min and Qd 500ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm.
Study NCT03288922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-efficiency OL-HDF
Description: The controlled modality High-efficiency OL-HDF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 400 ml/min and the total dialysis fluid flow rate was 800 ml/min which included post-filter substitution rate of 100 ml/min. The standard high-flux dialyzer that was used was HF80s from Fresenius Medical Care, Germany contains 1.8 m2 hollow fiber polysulfone membrane (ultrafiltration coefficient 55 ml/h/mmHg; urea clearance 248 ml/min, Qb 300ml/min and Qd 500 ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm.
Study NCT03512379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIANJI Robot
Description: A robotic system for spinal surgery
Study NCT03512379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy
Description: For fluoroscopy-based free hand surgery
Study NCT03512379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigation
Description: For navigation-assisted spinal surgery
Study NCT00349778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in \~250 mL of saline or D5W and infused IV over 2 hours
Study NCT00349778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg etoposide as 5 mL solution in clear ampules for injection.
Study NCT02946736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FSSB/Sleep Leadership Training
Description: Supervisors will receive a training addressing family-supportive supervisor behaviors and sleep leadership.
Study NCT02946736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Actigraphy Feedback
Description: Supervisors and employees will receive personalized feedback on their sleep and activity measurements.
Study NCT03072927 — intervention group
Intervention type: DEVICE
Intervention: MILD
Description: MILD is performed under fluoroscopic image guidance through an ipsilateral interlaminar dorsal approach to the spine. Following epidurography, partial decompression is performed through the removal of tissue and bone at the symptomatic level confirmed with correlated MRI and clinical findings.
Study NCT03072927 — intervention group
Intervention type: DEVICE
Intervention: Interspinous Process Decompression
Description: Interspinous Process Decompression
Study NCT04301557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Antibody
Description: PD-1 antibody 240mg,I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment, and four cycles in the adjuvant treatment,
Study NCT04301557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxiliplatin 130mg/m\^2 (100mg/m\^2 during radiotherapy),I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen
Study NCT04301557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m\^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen
Study NCT04301557 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: Neoadjuvant radiotherapy, 50Gy/25Fractions to the GTV, 45Gy/25Fractions to the CTV
Study NCT04301557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision
Description: Total mesorectal excision
Study NCT00682539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (Avastin)
Description: The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
Study NCT00682539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
Study NCT00682539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
Study NCT00682539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: The intravitreal injection of Ranibizumab (Lucentis®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.05ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
Study NCT00511602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin
Description: Technosphere Insulin Inhalation Powder
Study NCT00511602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Technosphere Placebo
Description: Technosphere Inhalation Powder
Study NCT02207634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Study NCT02207634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Study NCT02207634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Statin Therapy
Description: Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
Study NCT02207634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background Statin Therapy
Description: Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
Study NCT02757755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AB-SA01 (10^8 PFU per phage)
Description: Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
Study NCT02757755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AB-SA01 (10^9 PFU per phage)
Description: Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
Study NCT02757755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (for Cohort 10^8)
Description: Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
Study NCT02757755 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (for Cohort 10^9)
Description: Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
Study NCT02920801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: 5mg per day for 12 weeks
Study NCT02920801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1500mg per day for 12 weeks
Study NCT02347059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-dopa
Description: Antiparkinsonian medication
Study NCT02347059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine Agonists (pramipexole, ropirinole)
Description: Antiparkinsonian medication
Study NCT05941312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous products
Description: After the operation area was washed thoroughly with saline, autologous products were placed inside defects according to the related group. For the control group, the defects were left without adding any products.
Study NCT00302653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: Rasburicase 0,20mg/Kg/Day once a day 3-7 days
Study NCT03222310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib 100 mg tablet orally once daily.
Study NCT03222310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 100 mg capsules orally once daily.
Study NCT00349778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.
Study NCT00349778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.
Study NCT00349778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.
Study NCT02975674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MT-12 dental implant
Description: Placement of the MT-12 dental implant with Morse taper implant-abutment connection
Study NCT02975674 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CON.INT dental implant
Description: Placement of the CON.INT dental implant with internal hexagon implant-abutment connection
Study NCT02462018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WalkAide
Description: Patiants with hemiplegic or asymmetric diplegic CP will use WalkAide device for 4 months .First month for adjustment and three months of daily using of the device.~For each patient two assessments will be conducted: at baseline and at post-intervention follow-up.~During the assessments each child will go through:~A. Medical interview and neurological and physical therapist examination. B. Motor function tests: 6 min walk test, Gross motor function measure (GMFM) ,Timed up and down stairs test (TUDS), walking on a ramp ,with and without the FES device.~C. Gait analysis test with and without FES device. D. Parents will be requested to complete questionnaires on the frequency of falling.~E. On the second assessment parents wiil be requested to complete a questionnaire about the compliance to the FES.
Study NCT01076387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open radical cystectomy
Description: Open radical cystectomy, pelvic lymph node dissection and open urinary diversion.
Study NCT01076387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic-assisted radical cystectomy
Description: Robotic radical cystectomy, pelvic lymph node dissection and open urinary diversion. Robotic radical cystectomy is routinely performed by robotically trained and experienced minimally invasive surgeons.
Study NCT00681733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
Study NCT00681733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 mg OD
Study NCT00681733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline
Description: 1200 mg/d
Study NCT02679287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLC
Description: The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
Study NCT01732016 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normobaric hypoxia chamber
Study NCT01725594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT 2003
Study NCT01725594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02303028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan and Pazopanib
Description: Low-dose metronomic Topotecan and Pazopanib will be escalated as per the dose escalation schema.
Study NCT02300740 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: NIAGEN, ChromaDex
Study NCT03051308 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: NPT and UW Solution
Description: Tissue preservation solutions for transplantation
Study NCT03320135 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel matrix derivative proteins
Description: Open flap debridement to enamel matrix derivative to treat proximal furcation involvements.
Study NCT03320135 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flap debridement
Description: Open flap debridement will be performed to decontaminate the proximal furcation involvements.
Study NCT01602068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate Ophthalmic
Description: Transcleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
Study NCT01602068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100 mM Sodium Citrate Buffer
Description: Transcleral iontophoresis delivery of 100 mM sodium citrate buffer solution
Study NCT00287612 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lap. Fundo. with Mobilization of the Esophageal Junction
Description: Complete mobilization of the esophageal junction
Study NCT00287612 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lap. Fundo. without Mobilization of the Esophageal Junction
Description: phrenoesophageal membrane left intact
Study NCT02109965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Continue infusion (CIF) 0.1 - 0.7 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2
Study NCT02109965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2